Johnson & Johnson (NYSE:JNJ) Shares Sold by Cambridge Trust Co.

Cambridge Trust Co. decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 269,325 shares of the company’s stock after selling 4,929 shares during the period. Johnson & Johnson makes up approximately 2.1% of Cambridge Trust Co.’s investment portfolio, making the stock its 8th largest position. Cambridge Trust Co.’s holdings in Johnson & Johnson were worth $47,576,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Trinity Legacy Partners LLC raised its holdings in Johnson & Johnson by 2.1% in the 4th quarter. Trinity Legacy Partners LLC now owns 29,457 shares of the company’s stock valued at $5,204,000 after acquiring an additional 598 shares during the last quarter. Richard P Slaughter Associates Inc increased its holdings in shares of Johnson & Johnson by 1.0% during the 4th quarter. Richard P Slaughter Associates Inc now owns 8,385 shares of the company’s stock worth $1,481,000 after buying an additional 87 shares during the last quarter. Radnor Capital Management LLC increased its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Radnor Capital Management LLC now owns 33,071 shares of the company’s stock worth $5,927,000 after buying an additional 100 shares during the last quarter. Parkside Advisors LLC increased its holdings in shares of Johnson & Johnson by 23.4% during the 4th quarter. Parkside Advisors LLC now owns 3,879 shares of the company’s stock worth $685,000 after buying an additional 735 shares during the last quarter. Finally, Brookstone Capital Management increased its holdings in shares of Johnson & Johnson by 0.9% during the 4th quarter. Brookstone Capital Management now owns 57,325 shares of the company’s stock worth $10,333,000 after buying an additional 491 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $152.38 on Friday. The stock has a market cap of $396.84 billion, a P/E ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The company has a fifty day simple moving average of $161.97 and a 200-day simple moving average of $167.88. Johnson & Johnson has a 12-month low of $150.71 and a 12-month high of $186.69. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the previous year, the company earned $2.13 EPS. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating for the company. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.